ARTL Stock Performance, Insider Transaction and News

ARTL - Artelo Biosciences, Inc.

Market Cap	5.63M	P/E	-	EPS this Y	44.30%	Ern Qtrly Grth	-
Income	-10.44M	Forward P/E	-1.70	EPS next Y	42.30%	50D Avg Chg	1.00%
Sales	-	PEG	-	EPS past 5Y	-	200D Avg Chg	-21.00%
Dividend	N/A	Price/Book	0.32	EPS next 5Y	-	52W High Chg	-73.00%
Recommedations	1.70	Quick Ratio	5.96	Shares Outstanding	3.23M	52W Low Chg	42.00%
Insider Own	0.83%	ROA	-54.33%	Shares Float	3.20M	Beta	1.37
Inst Own	0.80%	ROE	-88.58%	Shares Shorted/Prior	36.26K/37.34K	Price	1.97
Gross Margin	-	Profit Margin	-	Avg. Volume	12,629	Target Price	-
Oper. Margin	-	Earnings Date	Nov 11	Volume	9,328	Change	0.00%

Healthcare | Biotechnology | United States

About Artelo Biosciences, Inc.

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Artelo Biosciences, Inc. News

11/18/24	Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit
11/13/24	Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium
11/12/24	Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
11/05/24	Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program
10/09/24	Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th
09/04/24	Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/13/24	Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
07/15/24	Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor
07/03/24	Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium
07/02/24	Artelo Biosciences Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform
07/01/24	Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium
06/04/24	Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society
05/29/24	Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24
05/13/24	Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
05/10/24	Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th
04/23/24	Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
04/22/24	Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time
03/25/24	Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
03/12/24	Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge
02/15/24	Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th

ARTL Chatroom

Ryantimothy89 Posted - 2 days ago

$ARTL slowly adding more on bid fills today. ill take it

ANTHONYMOMO Posted - 2 days ago

$DGLY $0.73 nano float 2m. big news out. $PRFX $ARTL

Ryantimothy89 Posted - 2 days ago

$ARTL nice updates yesterday. decent ER recently with 4-5x PTs. continuing to build a position

GigaStocks Posted - 2 days ago

$ARTL super low float of 3M, can run up on little volume.

nobodyspecial07 Posted - 3 days ago

$AZI Moving up towards the top 10 to join $HCWB, $SINT, & $ARTL. $HCWB is a real monster today!

14kmaker Posted - 3 days ago

$ARTL this one can really rocket up fast

JimmyJohnnyBoy Posted - 3 days ago

$ARTL be very careful here, Moon market weak handed Goons on this. May end below 1 by end of day if FLYE was an example

MisterPips Posted - 3 days ago

$ARTL Thoughts on this stock?

thetoptrader619 Posted - 3 days ago

$ARTL SOLANA BEACH, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological and neurological conditions, today announced that Professor Saoirse O'Sullivan, Vice President of Translational Sciences at Artelo, will be presenting at the 7th Cannabinoid-Derived Drug Development Summit. The event will take place November 18-20, 2024, at the Wyndham Beacon Hill Hotel in Boston, MA. Key data from Artelo's development programs will be highlighted in three separate sessions titled: Fatty Acid-Binding Protein 5 (FABP5) Inhibitors as Novel Therapeutics (featuring ART26.12) ART27.13: A Peripherally Selective CB1/CB2 Agonist for Cancer Cachexia ART12.11: A Novel Cannabidiol Cocrystal Demonstrating a Pharmacokinetic Profile Comparable to Epidiolex® in Rats - Added ARTL 1.13 for swing on this news

LongBallBarn Posted - 3 days ago

$PULM $ARTL $VTVT

Waham Posted - 3 days ago

$ARTL 🥶

2TrustHim Posted - 3 days ago

$ARTL Low Float and $5.00 Price Target!!!

thetoptrader619 Posted - 3 days ago

$ARTL added for swing

thetoptrader619 Posted - 3 days ago

Gunther77 Posted - 6 days ago

$ARTL $3.5m cap. How is that even possible? How far can this drop with such a low float. There are total 💩 stocks out there with more cap. Let's go ahead and do a 4 for 1 reverse split right now. Maybe we can get some action with 800k shares.

type12 Posted - 1 week ago

$ARTL Hold or ditch?

KavaStocks Posted - 2 weeks ago

$ARTL Might be time to revisit. What say you, Greg?

kaefer Posted - 2 weeks ago

$ARTL GO‼️‼️‼️

nikolatesla420 Posted - 2 weeks ago

$ARTL found out why

nikolatesla420 Posted - 2 weeks ago

$ARTL why are we moving?

xxGroundZeroxx Posted - 10/30/24

$ARTL will this ever get ❤️ $DRUG $SGBX

14kmaker Posted - 10/29/24

$ARTL this one has been moving a little after hours

thetoptrader619 Posted - 1 month ago

$ARTL untouched bio. Loaded at 1.19 for tmrw

Jacks10 Posted - 1 month ago

$ARTL let's wake up to $2+

rk39842 Posted - 1 month ago

$ARTL this stock deserves an award for remaining over $1 without any catalyst or major pipeline

Ryantimothy89 Posted - 1 month ago

$ARTL added here with low float bios flying. 3m float with recent buy rating and $5 and $6 PTs. CEO to participate in fireside chat today 👀🔥🚀

Gunther77 Posted - 1 month ago

$ARTL we have slowly 🐌 been hitting lower lows and lower highs. What are they going to do when we dip below one? This stock has been so mismanaged that it should be criminal.

Stocksrunner Posted - 1 month ago

🚀 Big analyst moves today! From $ARTL getting a fresh Buy to $BDX, $CRM, $DDOG, and $F also upgraded. 📈 Check out why these stocks are making headlines and what it could mean for your next investment https://stocksrunner.com/posts/1222

Article_AI Posted - 1 month ago

$ARTL Artelo Biosciences initiated with a Buy at EF Hutton EF Hutton initiated coverage of Artelo Biosciences with a Buy rating and $6 price target Artelo is an emerging biotechnology company focused on cac... https://www.stck.pro/news/ARTL/90416757/

topstockalerts Posted - 09/23/24

Pre Market Top Gainers PT2 $SGN $LGCB $ARTL $BHVN $WHLR

Analyst Ratings

HC Wainwright & Co.	Buy	Aug 14, 24
HC Wainwright & Co.	Buy	Jun 5, 24
HC Wainwright & Co.	Buy	May 15, 24
HC Wainwright & Co.	Buy	Apr 2, 24
HC Wainwright & Co.	Buy	Nov 14, 23
Ladenburg Thalmann	Buy	Apr 3, 23
HC Wainwright & Co.	Buy	Feb 3, 23
HC Wainwright & Co.	Buy	Aug 12, 22

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
Gorgas Gregory D.	Pres, CEO, CFO, Trea.. Pres, CEO, CFO, Treas & Secr	Aug 12	Buy	4.00	1,200	4,800	2,400	08/12/22
Gorgas Gregory D.	Pres, CEO, CFO, Trea.. Pres, CEO, CFO, Treas & Secr	Aug 11	Buy	4.03	1,200	4,836	1,200	08/11/22